Genstar Capital Portfolio Company Univita Health Completes Debt Financing
SAN FRANCISCO, July 22 /PRNewswire/ -- Genstar Capital, LLC, a middle market private equity firm that focuses on investments in selected segments of the industrial technology, life sciences, healthcare services, business services and software services industries, today announced that its...Burrill Merchant Banking Advises Pfizer Inc. on Dermatology Portfolio Divestment
SAN FRANCISCO, July 14 /PRNewswire/ -- Burrill Merchant Banking acted as exclusive financial advisor to Pfizer Inc. on its recently-completed divestment of three investigational compounds for dermatological conditions to Graceway Pharmaceuticals, LLC. Financial terms of the agreement we...Clinical Genomics Continues Progress in Developing Biomarker Portfolio for Colorectal Cancer Testing
SYDNEY, April 29 /PRNewswire/ -- Clinical Genomics Pty Ltd, an Australian biotechnology company, announced today that Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, has agreed to provide milestone payments over the next two years t...Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
BASINGSTOKE, England and CAMBRIDGE Massachusetts, July 3 /PRNewswire-FirstCall/ -- - Shire proposes acquisition of biotechnology company, Jerini AG for an equity purchase price of EUR328 million adding hereditary angioedema (HAE) product, FIRAZYR(R), to its Human Genetic Therapies (HGT) ...Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins
Lead Candidate Set for Phase II Clinicals LA JOLLA, Calif., June 11 /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc. (OTC Bulletin Board: DSKA) ("Duska" or the "Company"), announced today that it has been granted an exclusive, worldwide license from Duke University and Johns H...Isis Highlights Robust Drug Portfolio for Diabetes and Obesity at ADA Conference
- Oral presentation on the potent blood glucose lowering effect of SGLT2 antisense inhibitors in multiple preclinical models - Eight additional presentations highlight significant activity in eight new metabolic disease targets utilizing antisense SAN FRANCISCO and CARLSBA...Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio
Review Zanolimumab Program to be Discontinued and Headcount to be Reduced Summary: Genmab Announces the Results of its Portfolio Review; Zanolimumab Program to be Discontinued and the Company Will Reduce the Number of Employees COPENHAGEN, October 8 /PRNewswire-F...Roche OMNI S Blood Gas Analyzer
Description:... Roche OMNI S is the next generation Critical Care Analyzer completes and extends the Roche product portfolio for Hospital Point of Care applications. The modular concept allows to customize the comprehensive parameter menu as well as analyzer features exactly...Olympus broadens portfolio with new biliary metallic stent
CENTER VALLEY, Pa., June 1, 2009 Olympus America Inc. today expanded its medical portfolio by introducing the X-Suit NIR, a biliary metallic stent designed with exceptional anatomic conformability and superior radial support. The X-Suit NIR's proprietary NIRflex cell design provides a physician s...Springer expands its portfolio in plant sciences with Phytoparasitica
Phytoparasitica is an international journal that publishes original research contributions on the biological, chemical and molecular aspects of entomology, plant pathology, virology, nematology and weed sciences, including insecticides, fungicides, herbicides and other biocides. Emphasis is on ...Lockheed Martin Advances Biometrics Portfolio Through Cooperation Agreement With Cognitec
Partnership with Facial Recognition Expert Supports Open, Innovative Solutions GAITHERSBURG, Md., Dec. 18 /PRNewswire-FirstCall/ -- Lockheed Martin [NYSE: LMT] further advanced its capabilities and offerings in biometrics solutions through a cooperation agreemen...MWG Biotech expands siMAX?siRNA portfolio with new scales, lengths and design tools
University of Utah researchers showed that a fruit fly gene is crucial for determining when juveniles begin to mature into adults, and how the transformation initially proceeds. Understanding this process in humans may help explain how adorable children become surly teenagers. When the DHR4 gene ...Fujitsu Expands Support for Ethernet Networks With New Additions to XG Switch Product Line
...ely low failure rates in a compact form factor, creating an ideal environment for Enterprise deployment. Adding the 1GbE/10GbE Switches to the company portfolio will further strengthen its position in the market and offer comprehensive product solutions to customers. The combined Fujitsu XG product line will ...$20 million NIH grant to transform clinical research at UIC
...ational Science. The grant is the largest in UIC's history. "The CCTS draws upon the rich intellectual breadth of the UIC campus and adds to the portfolio of excellent research that is underway on the campus," said Paula Allen-Meares, UIC chancellor. Translational research -- moving new, basic science...Shire plc: Core Portfolio of Products Delivers 20% Sales Growth
DUBLIN, August 5 /PRNewswire-FirstCall/ -- - 2009 Guidance Framework Reaffirmed Shire plc (LSE: SHP, NASDAQ: SHPGY ) the global specialty biopharmaceutical company, announces results for the three months to June 30, 2009. Q2 2009 Financial Highlights ...ERT to Showcase Its Clinical Trials Portfolio at DIA's 45th Annual Meeting at Booth #507
PHILADELPHIA, June 15 /PRNewswire/ -- ERT (Nasdaq: ERES ), a leading provider of centralized ECG and eClinical technology, ePRO, and other services to the biopharmaceutical, medical device, and related industries, announced today that it will be showcasing its portfolio of products an...ERT to Showcase Its Clinical Trials Portfolio at DIA's 21st Euromeeting
PHILADELPHIA, March 12 /PRNewswire/ -- ERT, a leading provider of centralized ECG and eClinical technology, ePRO, and other services to the biopharmaceutical, medical device, and related industries, announced today that it will be showcasing its portfolio of products and services on Booth #1253/12...hKvLQT1/hminK-CHO K1 Recombinant Cell Line from Upstate
Description:...s a requirement for high quality research tools that will allow the full benefit of the new screening technologies to be realised. Upstate has built a portfolio of ion channel cell lines to meet these new and evolving needs in the drug discovery industry. Our ion channel cell lines are available off of the...hNav1.6-HEK293 Recombinant Cell Line from Upstate
Description:...s a requirement for high quality research tools that will allow the full benefit of the new screening technologies to be realised. Upstate has built a portfolio of ion channel cell lines to meet these new and evolving needs in the drug discovery industry. Our ion channel cell lines are available off of the...hKv1.5-CHO K1 Recombinant Cell Line from Upstate
Description:...s a requirement for high quality research tools that will allow the full benefit of the new screening technologies to be realised. Upstate has built a portfolio of ion channel cell lines to meet these new and evolving needs in the drug discovery industry. Our ion channel cell lines are available off of the...hHCN4-CHO K1 Recombinant Cell Line from Upstate
Description:...s a requirement for high quality research tools that will allow the full benefit of the new screening technologies to be realised. Upstate has built a portfolio of ion channel cell lines to meet these new and evolving needs in the drug discovery industry. Our ion channel cell lines are available off of the...hERG-CHO K1 Recombinant Cell Line from Upstate
Description:...s a requirement for high quality research tools that will allow the full benefit of the new screening technologies to be realised. Upstate has built a portfolio of ion channel cell lines to meet these new and evolving needs in the drug discovery industry. Our ion channel cell lines are available off of the...